Wednesday, June 10, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 12 of 1,261
  1. US 12421188

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  2. US 12421316

    Bispecific immunotoxins targeting human CD25+CCR4+ tumors and regulatory T-cells

    The Regents of the University of Colorado, a Body Corporate Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  3. US 12421302

    CAR-t cells and autoimmune diseases

    The Regents of the University of California Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  4. US 12419880

    Companion diagnostic tool for mutant p53 reactivating compounds

    PMV PHARMACEUTICALS, INC. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  5. US 12421220

    Bicyclic-substituted glutarimide cereblon binders

    C4 THERAPEUTICS, INC. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  6. US 12421269

    SGLT2/DPP4 inhibitor and application thereof

    CGeneTech (Suzhou, China) CO., Ltd. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  7. US 12421236

    Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor

    Medshine Discovery Inc. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  8. US 12421193

    GPR52 modulators and methods of use

    Neurocrine Biosciences, Inc. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  9. US 12421273

    Ectonucleotidase inhibitors and methods of use thereof

    ANTENGENE THERAPEUTICS LIMITED Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  10. US 12421231

    Azaindole derivatives and their use as ERK kinase inhibitors

    AGV Discovery Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  11. US 12419969

    AAV capsid variants and uses thereof

    VOYAGER THERAPEUTICS, INC. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  12. US 12421280

    Insulin like growth factor binding protein bioactive peptide fragments

    Northwestern University Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  13. US 12421517

    Genetic modification of mammalian cells to confer resistance to CSF1R antagonists

    The Regents of the University of California Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  14. US 12419955

    Method for efficiently infecting human natural killer cells and other immune cells with pseudovirus

    Beijing Gene MINK Biotechnology CO.LTD Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  15. US 12420113

    Methods and apparatus for applying tumor treating fields combined with personalized ultra-fractionated stereotactic adaptive radiotherapy

    The Board of Regents of the University of Texas System Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  16. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Mirati Therapeutics, Inc. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  17. US 12419920

    Bifidobacterium longum NCIMB 41676

    PrecisionBiotics Group Limited Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  18. US 12421253

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  19. US 12419831

    Hydrocortisone oral liquid formulations

    Eton Pharmaceuticals, Inc. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  20. US 12419963

    Diels-Alder conjugation methods

    REGENERON PHARMACEUTICALS, INC. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  21. US 12421282

    Compositions and methods for the treatment of metabolic and liver disorders

    Viking Therapeutics, Inc. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  22. US 12419870

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  23. US 12421292

    Anti-DLL3 chimeric antigen receptors and uses thereof

    Legend Biotech Ireland Limited Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted
  24. US 12419811

    Hydrogel drug delivery composition

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Sep 23, 2025 Β· Expires Sep 18, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.